Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 10/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.44 |
| ▸ | LTA4H | P09960 | 3/20 | 0.43 |
| ▸ | NR5A1 | Q13285 | 1/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 8/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 8/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 8/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 7/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29380253 | 0.91 | KMT2A (0.42) | CYP3A4MEN1NPC1ALDH1A1GAA | |
| SCHEMBL9669619 | 0.91 | KMT2A (0.42) | CYP3A4MEN1NPC1ALDH1A1GAA | |
| SCHEMBL8500796 | 0.85 | LNPEP (0.50) | CYP2D6MEN1ALDH1A1GAAKMT2A | |
| SCHEMBL8502419 | 0.85 | LNPEP (0.47) | CYP2D6ALDH1A1GAALNPEPCYP2C19 | |
| SCHEMBL5657197 | 0.84 | NOTUM (0.48) | CYP3A4MEN1NPC1ALDH1A1RAB9A | |
| SCHEMBL26462412 | 0.83 | NCF1 (0.46) | MEN1ALDH1A1MAPTKMT2ALNPEP | |
| SCHEMBL23554280 | 0.83 | NOS2 (0.44) | LNPEP | |
| SCHEMBL29550059 | 0.83 | NOS2 (0.44) | LNPEP | |
| SCHEMBL13097218 | 0.79 | LNPEP (0.43) | CYP2D6LNPEP | |
| SCHEMBL6376429 | 0.79 | MAOB (0.47) | CYP2D6LNPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12065409-B2 | Analogs of 2-pralidoxime as antidotes against organophosphorus nerve agents | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2024-08-20 | — | — | US | disclosed |
| US-20210317084-A1 | Analogs of 2-Pralidoxime as Antidotes Against Organophosphorus Nerve Agents | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2021-10-14 | — | — | US | disclosed |
| WO-2020027905-A2 | ANALOGS OF 2-PRALIDOXIME AS ANTIDOTES AGAINST ORGANOPHOSPHORUS NERVE AGENTS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2020-02-06 | — | — | WO | disclosed |
| EP-2646436-B1 | MONOBACTAMS | PFIZER (US) | 2015-05-27 | — | — | EP | disclosed |
| EP-2010535-B1 | THIOXANTHINE DERIVATIVES AND THEIR USE AS INHIBITORS OF MPO | ASTRAZENECA AB (SE) | 2012-07-11 | — | — | EP | disclosed |
| WO-2012073138-A1 | MONOBACTAMS | PFIZER INC. (US) | 2012-06-07 | — | — | WO | disclosed |
| US-8026244-B2 | Thioxanthine derivatives and their use as inhibitors of MPO | ASTRAZENECA AB (SE) | 2011-09-27 | — | — | US | disclosed |
| CN-101466712-A | Thioxanthine derivatives and their use as inhibitors of mpo | ASTRAZENECA AB (SE) | 2009-06-24 | — | — | CN | disclosed |
| US-20090149475-A1 | Thioxanthine Derivatives and Their Use as Inhibitors of MPO | ASTRAZENECA AB (SE) | 2009-06-11 | — | — | US | disclosed |
| EP-2010535-A1 | THIOXANTHINE DERIVATIVES AND THEIR USE AS INHIBITORS OF MPO | AstraZeneca AB (SE) | 2009-01-07 | — | — | EP | disclosed |
| WO-2007120098-A1 | THIOXANTHINE DERIVATIVES AND THEIR USE AS INHIBITORS OF MPO | ASTRAZENECA AB (SE) | 2007-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210317084-A1 | Analogs of 2-Pralidoxime as Antidotes Against Organophosphorus Nerve Agents | ACHE, DDT, BCHE | CYP2D6 186/4885CYP3A4 408/4885MEN1 625/4885 |
| US-12065409-B2 | Analogs of 2-pralidoxime as antidotes against organophosphorus nerve agents | ACHE, DDT, BCHE | CYP2D6 186/4885CYP3A4 408/4885MEN1 625/4885 |
| US-20090149475-A1 | Thioxanthine Derivatives and Their Use as Inhibitors of MPO | MPO, XDH, EPX | CYP2D6 1015/4885CYP3A4 1227/4885MEN1 3282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.